<p>This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.</p><p>If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [<sup>99m</sup>Tc]-labelled biphosphonates on bone scan.</p> <p>The presence of osteoblastic metastases which take up technetium [<sup>99m</sup>Tc]-labelled biphosphonates should be confirmed prior to therapy.</p></div>
Therapeutic Area (MeSH)
ATC Code
V10BX02
ATC Item
N/A
Pharmacotherapeutic Group
Therapeutic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| samarium (153Sm) lexidronam pentasodium | N/A | samarium (153Sm) lexidronam pentasodium |
EMA Name
Quadramet
Medicine Name
Quadramet
Aliases
N/ANo risk management plan link.
